AC Immune (NASDAQ:ACIU) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

AC Immune (NASDAQ:ACIU) announced its quarterly earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03, Zacks reports. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.

AC Immune Trading Up 4.9%

Shares of ACIU traded up $0.16 during midday trading on Tuesday, reaching $3.34. 359,367 shares of the company were exchanged, compared to its average volume of 189,583. The stock has a 50-day moving average price of $2.83 and a 200-day moving average price of $2.25. The company has a market cap of $334.87 million, a price-to-earnings ratio of -5.75 and a beta of 1.56. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AC Immune stock. Acadian Asset Management LLC increased its holdings in AC Immune (NASDAQ:ACIU) by 87.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 371,177 shares of the company’s stock after acquiring an additional 172,796 shares during the quarter. Acadian Asset Management LLC owned approximately 0.37% of AC Immune worth $679,000 as of its most recent filing with the SEC. 51.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ACIU has been the topic of a number of research reports. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research note on Monday, September 8th. Zacks Research upgraded AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.